We are delighted to announce that our partner, IMIDomics, has licensed their first-in-class anti-CD226 (DNAM-1) monoclonal antibody (mAb) program to Formation Bio. This program, which was originated from research at the University of Tsukuba and TNAX Biopharma, is IND-cleared and will be clinically developed by Riverview Bio, a new company recently founded by Formation Bio, with an initial focus on ulcerative colitis.
This collaboration underscores the significant potential of this innovative treatment for patients with immune-mediated inflammatory diseases (IMIDs) who are currently underserved by existing therapies.
For full details, please refer to IMIDomics’ press release: https://www.prnewswire.com/news-releases/formation-bio-licenses-first-in-class-anti-cd226-autoimmune-program-from-imidomics-302515217.html